Abstract
Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.
| Original language | English |
|---|---|
| Pages (from-to) | 542-552 |
| Number of pages | 11 |
| Journal | Clinics and Research in Hepatology and Gastroenterology |
| Volume | 42 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2018 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma : Five-year retrospective study. / Liu, Yi-Sheng; Lin, Chia-Ying; Chuang, Ming-Tsung; Tsai, Yi-Shan; Wang, Chien-Kuo; Ou, Ming-Ching.
In: Clinics and Research in Hepatology and Gastroenterology, Vol. 42, No. 6, 01.12.2018, p. 542-552.Research output: Contribution to journal › Article
TY - JOUR
T1 - Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma
T2 - Five-year retrospective study
AU - Liu, Yi-Sheng
AU - Lin, Chia-Ying
AU - Chuang, Ming-Tsung
AU - Tsai, Yi-Shan
AU - Wang, Chien-Kuo
AU - Ou, Ming-Ching
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.
AB - Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.
UR - http://www.scopus.com/inward/record.url?scp=85047647755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047647755&partnerID=8YFLogxK
U2 - 10.1016/j.clinre.2018.04.009
DO - 10.1016/j.clinre.2018.04.009
M3 - Article
VL - 42
SP - 542
EP - 552
JO - Clinics and Research in Hepatology and Gastroenterology
JF - Clinics and Research in Hepatology and Gastroenterology
SN - 2210-7401
IS - 6
ER -